Skip to content
Screener

AnaptysBio, Inc. ANAB Q1 2025 earnings

Reported May 5, 2025 · Before market open

Revenue$27.8MBeat by $12.5M
EPS-$1.28Beat by $0.02
Revenue estimate$15.3M
EPS estimate-$1.30

Next report

Nov 10, 2026 (in 2 months)
Revenue estimate$14.0M
EPS estimate$0.11

Financials

Q1 2025

Income statement

See full
Revenue$27.8M+287%
Operating income-$27.5M+34.7%
Net income-$39.3M+10.5%
EPS (diluted)-$1.28+22.0%

Balance sheet

See full
Cash & equivalents$98.6M+83.7%
Total debt$15.6M-10.4%
Total equity$34.0M-28.8%
Total assets$422.1M+4.0%

Cash flow

See full
Operating cash flow-$10.7M+71.3%
CapEx$35.0K+29.6%
Free cash flow-$10.7M+71.2%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$570.1M-5.4%
Enterprise value$487.03M-14.0%
P/S5.1×-21.2×

Profitability

See full
Operating margin-89.6%-41.8pp
Net margin-125.7%-56.8pp
FCF margin-97.6%-44.3pp

Returns & leverage

See full
Return on equity-343.8%-1,012pp
Debt / equity0.5×+0.1×
Current ratio8.2×-3.3×

FAQ

When did AnaptysBio, Inc. report Q1 2025 earnings?
AnaptysBio, Inc. (ANAB) reported Q1 2025 earnings on May 5, 2025 before market open.
What were AnaptysBio, Inc.'s Q1 2025 revenue and EPS?
AnaptysBio, Inc. reported revenue of $27.8M and eps of $-1.28 for Q1 2025.
Did AnaptysBio, Inc. beat estimates in Q1 2025?
Revenue beat the consensus estimate of $15.3M by $12.5M. EPS beat the consensus estimate of $-1.30 by $0.02.
How did AnaptysBio, Inc.'s Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 286.8% from $7.2M a year earlier and eps grew 22.0% from $-1.64.
Where can I find AnaptysBio, Inc.'s Q1 2025 SEC filings?
You can read the 8-K earnings release (0001370053-25-000045) and the 10-Q periodic report (0001370053-25-000046) directly on SEC EDGAR. The filing index links above go to sec.gov.